Hint? “No evidence of residual …. Tumor.” Dr. Ashkan (three years after surgery)
If its MOA is removing residual tumor, that would be a huge tell and correlate with the residual tumor signal over and above the ECA curve for its counter part, which was in the slide deck at NYAS.
Remember, residual tumor initially exposed to SOC can morph the tumor towards an aggressive mesenchymal subtype that also becomes hypermutated, thereby, it follows, making it more vulnerable to DCVax-l.
(Any similar MOA pattern corroborated in DCVax-l against recurrent would change the face of cancer therapy)
Market Data 
Markets 
AI
